ResMed Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Direxion Daily TSLA Bull 2X Shares trades at $9.74. The key difference: ResMed Inc. pays a 1.19% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and ResMed Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| RMD | TSLL | |
|---|---|---|
Market Cap | $31.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $283.28 | $23.03 |
52-Week Low | $182.82 | $6.74 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $9.87, up 7.87% on strong Tesla momentum ahead of the Cybercab event. The technical outlook is bullish with moving averages supporting upward momentum, while oscillators remain neutral. Recent news highlights investor enthusiasm for leveraged Tesla exposure, though the ETF's structure amplifies volatility risks.
The outlook remains driven by Tesla's performance, with potential upside from product launches but significant risk from daily rebalancing effects. Investors face amplified gains or losses relative to Tesla, requiring careful risk management given the ETF's leveraged structure and Tesla's inherent stock volatility.
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →